DRUGGABLE MM THERAPEUTICS: PATHOGENETIC PATHWAYS

por Ocio, Enrique M
Publicado 2022

The DAC system and associations with multiple myeloma

por Ocio, Enrique M., San Miguel, Jesús F.
Publicado 2010

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression

por Maiso, Patricia, Mogollón, Pedro, Ocio, Enrique M., Garayoa, Mercedes
Publicado 2021

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

por Mogollón, Pedro, Díaz-Tejedor, Andrea, Algarín, Esperanza M., Paíno, Teresa, Garayoa, Mercedes, Ocio, Enrique M.
Publicado 2019

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma

por Higuero Saavedra, Víctor, González-Calle, Verónica, Sobejano, Eduardo, Sebastiá, Josefa, Cabrero, Mónica, Bastida, Jose María, Puig, Noemi, Ocio, Enrique M., Mateos, María-Victoria
Publicado 2019

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

por Mateos, María-Victoria, Bladé, Joan, Bringhen, Sara, Ocio, Enrique M, Efebera, Yvonne, Pour, Luděk, Gay, Francesca, Sonneveld, Pieter, Gullbo, Joachim, Richardson, Paul G.
Publicado 2020

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

por Ocio, Enrique M., Bringhen, Sara, Martinez-Lopez, Joaquin, San-Miguel, Jesus, Oliva, Stefania, Rodriguez-Otero, Paula, Le Roux, Nadia, Dong, Yvonne, Doroumian, Severine, Macé, Sandrine, Mateos, Maria-Victoria
Publicado 2023

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines

por Paíno, Teresa, Sarasquete, María E., Paiva, Bruno, Krzeminski, Patryk, San-Segundo, Laura, Corchete, Luis A., Redondo, Alba, Garayoa, Mercedes, García-Sanz, Ramón, Gutiérrez, Norma C., Ocio, Enrique M., San-Miguel, Jesús F.
Publicado 2014

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease

por Garcia-Gomez, Antonio, Las Rivas, Javier De, Ocio, Enrique M., Díaz-Rodríguez, Elena, Montero, Juan C., Martín, Montserrat, Blanco, Juan F., Sanchez-Guijo, Fermín M., Pandiella, Atanasio, San Miguel, Jesús F., Garayoa, Mercedes
Publicado 2014

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

por Leleu, Xavier, Martin, Thomas, Weisel, Katja, Schjesvold, Fredrik, Iida, Shinsuke, Malavasi, Fabio, Manier, Salomon, Chang-Ki Min, Ocio, Enrique M., Pawlyn, Charlotte, Perrot, Aurore, Quach, Hang, Richter, Joshua, Spicka, Ivan, Yong, Kwee, Richardson, Paul G.
Publicado 2022

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma

por Paíno, Teresa, González-Méndez, Lorena, San-Segundo, Laura, Corchete, Luis A., Hernández-García, Susana, Díaz-Tejedor, Andrea, Algarín, Esperanza M., Mogollón, Pedro, Martín-Sánchez, Montserrat, Gutiérrez, Norma C., Mateos, María-Victoria, Garayoa, Mercedes, Ocio, Enrique M.
Publicado 2020

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

por Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee
Publicado 2020

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

por Mateos, María Victoria, Prosper, Felipe, Martin Sánchez, Jesús, Ocio, Enrique M., Oriol, Albert, Motlló, Cristina, Michot, Jean‐Marie, Jarque, Isidro, Iglesias, Rebeca, Solé, María, Martínez, Sara, Kahatt, Carmen, Fudio, Salvador, Corral, Gema, Zeaiter, Ali, Montilla, Lola, Ribrag, Vincent
Publicado 2022

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

por Garcia-Gomez, Antonio, Ocio, Enrique M., Crusoe, Edvan, Santamaria, Carlos, Hernández-Campo, Pilar, Blanco, Juan F., Sanchez-Guijo, Fermin M., Hernández-Iglesias, Teresa, Briñón, Jesús G., Fisac-Herrero, Rosa M., Lee, Francis Y., Pandiella, Atanasio, San Miguel, Jesús F., Garayoa, Mercedes
Publicado 2012

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

por Mikhael, Joseph, Richter, Joshua, Vij, Ravi, Cole, Craig, Zonder, Jeffrey, Kaufman, Jonathan L., Bensinger, William, Dimopoulos, Meletios, Lendvai, Nikoletta, Hari, Parameswaran, Ocio, Enrique M., Gasparetto, Cristina, Kumar, Shaji, Oprea, Corina, Chiron, Marielle, Brillac, Claire, Charpentier, Eric, San-Miguel, Jesús, Martin, Thomas
Publicado 2020

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

por Algarín, Esperanza M., Quwaider, Dalia, Campos-Laborie, Francisco J., Díaz-Tejedor, Andrea, Mogollón, Pedro, Vuelta, Elena, Martín-Sánchez, Montserrat, San-Segundo, Laura, González-Méndez, Lorena, Gutiérrez, Norma C., García-Sanz, Ramón, Paíno, Teresa, De Las Rivas, Javier, Ocio, Enrique M., Garayoa, Mercedes
Publicado 2021

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

por Hernández-García, Susana, San-Segundo, Laura, González-Méndez, Lorena, Corchete, Luis A., Misiewicz-Krzeminska, Irena, Martín-Sánchez, Montserrat, López-Iglesias, Ana-Alicia, Algarín, Esperanza Macarena, Mogollón, Pedro, Díaz-Tejedor, Andrea, Paíno, Teresa, Tunquist, Brian, Mateos, María-Victoria, Gutiérrez, Norma C, Díaz-Rodriguez, Elena, Garayoa, Mercedes, Ocio, Enrique M
Publicado 2017

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autolog...

por Ocio, Enrique M., Perrot, Aurore, Bories, Pierre, San-Miguel, Jesus F., Blau, Igor W., Karlin, Lionel, Martinez-Lopez, Joaquin, Wang, Song-Yau, Bringhen, Sara, Marcatti, Magda, Mateos, María-Victoria, Rodriguez-Otero, Paula, Oliva, Stefania, Nogai, Axel, Le Roux, Nadia, Dong, Liyan, Macé, Sandrine, Gassiot, Matthieu, Fitzmaurice, Thomas, Oprea, Corina, Moreau, Philippe
Publicado 2023

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

por López-Iglesias, Ana-Alicia, Herrero, Ana B., Chesi, Marta, San-Segundo, Laura, González-Méndez, Lorena, Hernández-García, Susana, Misiewicz-Krzeminska, Irena, Quwaider, Dalia, Martín-Sánchez, Montserrat, Primo, Daniel, Paíno, Teresa, Bergsagel, P. Leif, Mehrling, Thomas, González-Díaz, Marcos, San-Miguel, Jesús F., Mateos, María-Victoria, Gutiérrez, Norma C., Garayoa, Mercedes, Ocio, Enrique M.
Publicado 2017

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

por Spicka, Ivan, Ocio, Enrique M., Oakervee, Heather E., Greil, Richard, Banh, Raymond H., Huang, Shang-Yi, D’Rozario, James M., Dimopoulos, Meletios A., Martínez, Sara, Extremera, Sonia, Kahatt, Carmen, Alfaro, Vicente, Carella, Angelo M., Meuleman, Nathalie, Hájek, Roman, Symeonidis, Argiris, Min, Chang-Ki, Cannell, Paul, Ludwig, Heinz, Sonneveld, Pieter, Mateos, María Victoria
Publicado 2019